Search

Your search keyword '"Rassl, Doris M."' showing total 223 results

Search Constraints

Start Over You searched for: Author "Rassl, Doris M." Remove constraint Author: "Rassl, Doris M."
223 results on '"Rassl, Doris M."'

Search Results

1. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer

5. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

6. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

7. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

8. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

9. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

10. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

11. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

12. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

13. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

14. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

15. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

16. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study

17. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders

19. Data from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

20. Supplementary Table S5 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

21. Supplementary Figures S1 to S16 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

22. Supplementary Methods and References from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

23. Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

24. Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

25. Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma

31. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification

33. Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma

34. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

35. A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer

37. MesobanK UK: an international mesothelioma bioresource

39. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis

41. LUNG CANCER EVOLUTION: Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

43. ctDNA detection by personalised assays in early-stage NSCLC

44. Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

46. Additional file 2 of Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)

50. Extensive heterogeneity in somatic mutation and selection in the human bladder

Catalog

Books, media, physical & digital resources